soul trial oral semaglutide cardiovascular outcomes (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Semaglutide and Cardiovascular Outcomes in

GLP-1 receptor agonists, also known as GLP-1 analogues, reduce blood sugar levels and appetite

L., Weimann, A

At a dose of 1-2 mg per day, a single 50 mg vial could theoretically last 25-50 days, but you need to use it within 28 days after reconstitution

And I always think that's an important balance

The gradual dose-escalation protocol used in clinical trials is specifically designed to minimise their impact

The Benefits of GHK-Cu Peptides Topical and How to Use Them With Micro-Infusion: A Complete In-Depth Guide Share GHK-Cu peptides have become one of the most advanced and sought-after skincare ingredients in modern aesthetic science